Table 3

Efficacy in various PD-L1 expression types

Groups	T^H + LEC^H			T^H + LEC^L			T^L + LEC^L
Groups	TQB2450 (n = 15)	TQB2450 + An 10 mg (n = 21)	TQB2450 + An 12 mg (n = 22)	TQB2450 (n = 5)	TQB2450 + An 10 mg (n = 3)	TQB2450 + An 12 mg (n = 5)	TQB2450 (n = 3)	TQB2450 + An 10 mg (n = 1)	TQB2450 + An 12 mg (n = 0)
DCR (%)	73 (11/15)	100 (21/21)	95 (21/22)	100 (5/5)	100 (3/3)	100 (5/5)	67 (2/3)	100 (1/1)
P value	-	0.012*	0.053^#	-	-	-	-	-	-
P value			0.323^†			-			-
PFS (days) (95% CI)	82 (49–114)	159 (106–211)	209 (143–274)	55 (14–95)	452 (338–682)	126 (53–198)	42	168
HR (95% CI)	-	0.445* (0.210–0.939)	0.369^# (0.174–0.784)	-	0.115* (0.011–1.144)	0.425^# (0.107–1.689)	-	-	-
HR (95% CI)			0.832^† (0.450–1.539)			3.476^† (0.366–32.996)			-
P value	-	0.034*	0.009^#	-	0.065*	0.224^#	-	0.725*	-
P value			0.558^†			0.278^†			-

Groups	T^H + BEC^H			T^H + BEC^L			T^L + BEC^L
Groups	TQB2450 (n = 14)	TQB2450 + An 10 mg (n = 18)	TQB2450 + An 12 mg (n = 21)	TQB2450 (n = 6)	TQB2450 + An 10 mg (n = 6)	TQB2450 + An 12 mg (n = 6)	TQB2450 (n = 3)	TQB2450 + An 10 mg (n = 1)	TQB2450 + An 12 mg (n = 0)

DCR (%)	71 (10/14)	100 (18/18)	95 (20/21)	100 (6/6)	100 (6/6)	100 (6/6)	67 (2/3)	100 (1/1)	-
P value	-	0.015*	0.049^#	-	-	-	-	-	-
P value			0.348^†			-			-
PFS (days) (95% CI)	41 (2–79)	161 (104–217)	209 (145–272)	55 (24–85)	41 (30–51)	126 (119–132)	42	168	-
HR (95% CI)	-	0.340* (0.156–0.742)	0.340^# (0.159–0.727)	-	0.631* (0.164–2.31)	0.519^# (0.142–1.889)	-	-	-
HR (95% CI)			0.995^† (0.520–1.904)			0.838^† (0.238–2.953)			-
P value	-	0.007*	0.005^#	-	0.503*	0.320^#	-	0.725*	-
P value			0.987^†			0.784^†			-

↵*TQB2450 + An 10 mg vs. TQB2450; ^#TQB2450 + An 12 mg vs. TQB2450; †TQB2450 + An 12 mg vs. TQB2450 + An 10 mg. An, anlotinib; CI, confidence interval; DCR, disease control rate; HR, hazard ratio; PFS, progress free survival; T^H, PD-L1-positivity on cells ≥ 2.65%; T^L, PD-L1-positivity on cells < 2.65%; LEC^H, PD-L1-positivity on lymphatic endothelial cells ≥ 2.75%; LEC^L, PD-L1-positivity on lymphatic endothelial cells < 2.75%; BEC^H, PD-L1-positivity on vascular endothelial cells ≥ 4.59%; BEC^L, PD-L1-positivity on vascular endothelial cells < 4.59%.